Robert Reiter, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    04/15/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Lantheus
    Date added:
    Date updated:
    04/15/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Point biopharma
    Date added:
    Date updated:
    04/15/2025
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (Oncology)
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    04/15/2025
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (Specialty Not Specified)
    Ineligible company:
    Genomic Health
    Date added:
    Date updated:
    04/15/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    04/15/2025
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Specialty Not Specified)
    Ineligible company:
    ImaginAb Corporation
    Date added:
    Date updated:
    04/15/2025
Return to Curso en vivo de avances globales en cáncer de próstata: mejores prácticas en terapia hormonal (2022) - Espanol